Latest News about NVS
Recent news which mentions NVS
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
December 19, 2024
From Benzinga
From Benzinga
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
December 06, 2024
From Benzinga
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
December 03, 2024
From Benzinga
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
December 02, 2024
From Benzinga
2 Dividend Stocks to Buy and Hold Forever
December 01, 2024
From Motley Fool
Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline
November 21, 2024
From Benzinga
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
November 12, 2024
From Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
From Benzinga
From Benzinga
Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook
October 29, 2024
From Benzinga
Why Is Monte Rosa Therapeutics Stock Surging On Monday?
October 28, 2024
From Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
October 24, 2024
From Motley Fool
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
October 18, 2024
From Benzinga
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
October 18, 2024
From Benzinga
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
October 17, 2024
Tickers
NVS
From Motley Fool
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
October 16, 2024
From Benzinga
2 Magnificent Dividend Stocks to Buy and Hold Forever
October 14, 2024
From Motley Fool
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm
October 10, 2024
From Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
From Benzinga
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
September 18, 2024
From Benzinga
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
From Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
September 11, 2024
From Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
September 11, 2024
From Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
From Benzinga
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
September 05, 2024
From Benzinga
From Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.